Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive after announcing their conditional raise of around £25.5m.
Anson says this raise puts Redx in a 'much stronger financial position which allows us to drive forward our two key programmes, at pace'.
She goes on to explain the next step for their lead oncology asset, RXC004, with results from the Phase 1 study, expected in H1 2021.
Anson says 'our goal with this raise means we can now go straight into our phase II programme and really test the efficacy of this oncology drug, we estimate the start of this will also be in the first half of next year'.
The raise has also pushed forward the development compound in fibrosis, RXC007, which is set to enter the Phase 1 clinical development in H1 2021.